Maravai LifeSciences
Maravai LifeSciences' revenue fell 28.3% to $186 million in fiscal 2025. Its operating margin was −115.9%, down from −90.9% a year earlier. Free cash flow was −$71 million. The diluted share count rose 4.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Maravai LifeSciences does
Maravai LifeSciences supplies materials and services that drug companies and researchers use to develop drugs, vaccines and diagnostic tests. Its customers include large drug makers, young biotech firms, research organizations, universities and diagnostics companies.
It has two segments. TriLink, 64% of 2025 revenue, makes mRNA and other nucleic acids, which are the genetic building blocks of many vaccines and therapies. It sells research-grade and manufacturing-grade versions and mRNA manufacturing services. Its products include its patented CleanCap technology, which helps mRNA work properly in the body, and ModTail, which helps cells make more protein from mRNA. Cygnus, 36% of 2025 revenue, makes tests that detect leftover impurities, such as host cell proteins, in biologic drugs during manufacturing.
Maravai earns money by selling these products and services. It says some revenue comes from large-volume sales of CleanCap for vaccines, and that how long that lasts depends on factors outside its control. It competes with life science, drug and biotech companies that are much larger. It says it recently changed its organization, including its executive team and by cutting jobs, to lower costs.
Its biggest risks, as it describes them
- Customers cutting their spending on its products and services, which makes its results swing.
- Uncertainty about how long its high-volume CleanCap sales for commercial vaccines will last.
- Changes in US federal government policies that could affect it and its customers.
- Competing against much larger life science, drug and biotech companies that could make its products obsolete.
- Defects or quality problems with its reagents, which would damage customers' confidence.
Income statement
From fiscal 2020 to 2022, earnings per share fell 15.9% a year and net income grew 57.3% a year, as new shares raised the share count by 783% and diluted each share's earnings. Maravai LifeSciences then lost money in fiscal 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 551 | 632 | 575 | 322 | 217 |
| Debt incl. finance leases | 531 | 527 | 557 | 328 | 323 |
| Net debt (negative means net cash) | −21 | −105 | −18 | 5 | 106 |
| Net debt to EBITDA | −0.0x | −0.2x | −2.1x | — | — |
| Debt to equity | 1.7x | 1.0x | 1.3x | 1.0x | 1.5x |
| Interest coverage | 18.3x | 28.1x | −0.7x | −4.9x | −8.0x |
| Current ratio | 7.9x | 7.7x | 8.0x | 7.5x | 6.6x |
| Quick ratio | 7.3x | 7.3x | 7.4x | 6.7x | 5.7x |
Cash flow
Projections
Project Maravai LifeSciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Maravai LifeSciences says to expect
- Full year 2026: revenue
Revenue for the full year 2026 is expected to be in the range of $205.0 million to $215.0 million.
- Full year 2026: adjusted EBITDA
Adjusted EBITDA (non-GAAP) is now expected to be in the range of $33.0 million to $35.0 million, up from the prior range of $30.0 million to $32.0 million.
Insider trades
No officer, director or 10% owner of Maravai LifeSciences reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 4 of 9 | 2 of 9 |
| Rule of 40 | −46.3% | −18.9% | −66.4% |
| Altman Z'' | 4.37 | 2.71 | 1.29 |
| Accruals ratio | −13.0% | −12.2% | −8.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 4 of 9 | 4 of 9 | 2 of 9 |
Compare
Put Maravai LifeSciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Maravai LifeSciences | FY25 | −28.3% | −115.9% | −38.1% | −32.0% | — | 2 | |
| Cryoport | FY25 | 12.4% | −20.9% | −14.2% | −23.4% | — | 4 | Compare |
| Cytek Biosciences | FY25 | 0.5% | −20.0% | −4.3% | — | — | — | Compare |
| Ginkgo Bioworks | FY25 | −25.1% | −185.3% | −105.0% | — | — | — | Compare |
| PacBio | FY25 | 3.9% | −346.1% | −71.2% | −77.1% | — | 3 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 143 | 284 | 799 | 883 | 289 | 259 | 186 |
| Revenue growth | — | 98.5% | 181.3% | 10.5% | −67.3% | −10.3% | −28.3% |
| Gross profit | 76 | 204 | 659 | 714 | 140 | 108 | 34 |
| Research and development | 4 | 9 | 15 | 18 | 17 | 19 | 17 |
| Operating income | 24 | 120 | 555 | 574 | −32 | −236 | −215 |
| Net income | −4 | 89 | 182 | 220 | −119 | −145 | −131 |
| Diluted EPS (US$) | −0.03 | 2.36 | 1.56 | 1.67 | −0.90 | −1.05 | −0.90 |
| Diluted shares (millions) | 254 | 29 | 258 | 255 | 132 | 138 | 144 |
| Cash flow | |||||||
| Cash from operations | 24 | 152 | 369 | 536 | 126 | 8 | −58 |
| Capital expenditure | 17 | 25 | 15 | 17 | 66 | 30 | 13 |
| Free cash flow | 7 | 127 | 354 | 519 | 61 | −22 | −71 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 34 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 239 | 70 | 0 | 19 |
| Stock-based compensation | 2 | 25 | 10 | 19 | 35 | 49 | 30 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 25 | 236 | 551 | 632 | 575 | 322 | 217 |
| Debt incl. finance leases | — | 535 | 531 | 527 | 557 | 328 | 323 |
| Total assets | — | 1,271 | 1,918 | 2,282 | 1,488 | 1,008 | 771 |
| Total liabilities | — | 1,116 | 1,373 | 1,377 | 698 | 431 | 398 |
| Shareholders' equity | 145 | 88 | 316 | 545 | 417 | 325 | 212 |
| Margins and ratios | |||||||
| Gross margin | 53.3% | 72.0% | 82.4% | 80.9% | 48.5% | 41.8% | 18.3% |
| Operating margin | 16.8% | 42.2% | 69.4% | 65.0% | −10.9% | −90.9% | −115.9% |
| Net margin | −3.1% | 31.3% | 22.8% | 24.9% | −41.2% | −55.9% | −70.4% |
| Free cash flow margin | 4.9% | 44.6% | 44.3% | 58.8% | 21.0% | −8.6% | −38.1% |
| Rule of 40 (growth + FCF margin) | — | 143.1% | 225.6% | 69.2% | −46.3% | −18.9% | −66.4% |
| Return on capital | — | — | 100.3% | 77.1% | −2.0% | −27.5% | −32.0% |
| Return on equity | — | — | 90.1% | 51.2% | −24.8% | −39.0% | −48.6% |
| Return on assets | — | — | 11.4% | 10.5% | −6.3% | −11.6% | −14.7% |
| Net debt to EBITDA | — | 2.0x | −0.0x | −0.2x | −2.1x | — | — |